JP2025514872A - パーキンソン病の新規治療法としてのＭＨＣ １ｂを介したα－シヌクレイン特異的耐性誘導 - Google Patents

パーキンソン病の新規治療法としてのＭＨＣ １ｂを介したα－シヌクレイン特異的耐性誘導 Download PDF

Info

Publication number
JP2025514872A
JP2025514872A JP2024556456A JP2024556456A JP2025514872A JP 2025514872 A JP2025514872 A JP 2025514872A JP 2024556456 A JP2024556456 A JP 2024556456A JP 2024556456 A JP2024556456 A JP 2024556456A JP 2025514872 A JP2025514872 A JP 2025514872A
Authority
JP
Japan
Prior art keywords
seq
recombinant polypeptide
amino acid
domain
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514872A5 (https=
Inventor
ヴィシュフーゼン，イェルク
ブルッテル，ヴァレンティン
ワン アイピー，チー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of JP2025514872A publication Critical patent/JP2025514872A/ja
Publication of JP2025514872A5 publication Critical patent/JP2025514872A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024556456A 2022-03-24 2023-03-24 パーキンソン病の新規治療法としてのＭＨＣ １ｂを介したα－シヌクレイン特異的耐性誘導 Pending JP2025514872A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164123.6A EP4249506A1 (en) 2022-03-24 2022-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
EP22164123.6 2022-03-24
PCT/EP2023/057682 WO2023180548A1 (en) 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Publications (2)

Publication Number Publication Date
JP2025514872A true JP2025514872A (ja) 2025-05-12
JP2025514872A5 JP2025514872A5 (https=) 2026-02-20

Family

ID=81384775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556456A Pending JP2025514872A (ja) 2022-03-24 2023-03-24 パーキンソン病の新規治療法としてのＭＨＣ １ｂを介したα－シヌクレイン特異的耐性誘導

Country Status (12)

Country Link
US (1) US20250205321A1 (https=)
EP (2) EP4249506A1 (https=)
JP (1) JP2025514872A (https=)
KR (1) KR20240162549A (https=)
CN (1) CN119317639A (https=)
AU (1) AU2023238805A1 (https=)
CA (1) CA3250917A1 (https=)
CL (1) CL2024002724A1 (https=)
CO (1) CO2024012329A2 (https=)
IL (1) IL314741A (https=)
MX (1) MX2024011665A (https=)
WO (1) WO2023180548A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024344683A1 (en) * 2023-09-22 2026-04-02 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Also Published As

Publication number Publication date
MX2024011665A (es) 2024-09-27
CA3250917A1 (en) 2023-09-28
EP4249506A1 (en) 2023-09-27
CL2024002724A1 (es) 2025-02-14
CN119317639A (zh) 2025-01-14
WO2023180548A1 (en) 2023-09-28
IL314741A (en) 2024-10-01
AU2023238805A1 (en) 2024-07-18
EP4499682A1 (en) 2025-02-05
CO2024012329A2 (es) 2024-09-30
KR20240162549A (ko) 2024-11-15
US20250205321A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
US20250188145A1 (en) Tcr and peptides
JPH10504284A (ja) 抗原パルス化樹状細胞によるｉｎ ｖｉｖｏ Ｔ細胞活性化法
JP2016539635A (ja) 抗原特異的調節性ｔ細胞の誘導方法
JP2025514872A (ja) パーキンソン病の新規治療法としてのＭＨＣ １ｂを介したα－シヌクレイン特異的耐性誘導
JP2011504875A (ja) Ｓｔａｔ３エピトープペプチド
CN117586344B (zh) 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
US20250222083A1 (en) Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
JP2023536100A (ja) 代替の翻訳開始および翻訳停止に由来する多機能免疫グロブリンフォールドポリペプチド
EA052620B1 (ru) ОПОСРЕДОВАННАЯ MHC 1b ИНДУКЦИЯ СПЕЦИФИЧЕСКОЙ ДЛЯ АЛЬФАСИНУКЛЕИНА ТОЛЕРАНТНОСТИ В КАЧЕСТВЕ НОВОГО ЛЕЧЕНИЯ ПРОТИВ БОЛЕЗНИ ПАРКИНСОНА
US20250205322A1 (en) Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
AU2024344683A1 (en) Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
JP2021511054A5 (https=)
Fehlner et al. Murine T cell responses to melittin and its analogs
WO2007018198A1 (ja) Hla-a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬
US20250205323A1 (en) Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes
Seta et al. Characterization of autoreactive T-cell clones to myeloperoxidase in patients with microscopic polyangiitis and healthy individuals
Boon et al. Genes coding for tumor rejection antigens
Del Pozzo et al. Research Article Triggering DTH and CTL Activity by fd Filamentous Bacteriophages: Role of CD4+ T Cells in Memory Responses
CA2387391A1 (en) Hu antigen-derived peptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241007

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20241007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260212